Yoshihiko Terashima1, Shin Nishiumi2, Akihiro Minami1, Yuki Kawano1, Namiko Hoshi1, Takeshi Azuma1, Masaru Yoshida3. 1. Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chu-o-ku, Kobe, Hyogo 650-0017, Japan. 2. Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chu-o-ku, Kobe, Hyogo 650-0017, Japan. Electronic address: nishiums@med.kobe-u.ac.jp. 3. Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chu-o-ku, Kobe, Hyogo 650-0017, Japan; The Integrated Center for Mass Spectrometry, Kobe University Graduate School of Medicine, 7-5-1 Chu-o-ku, Kusunoki-cho, Kobe, Hyogo 650-0017, Japan; Division of Metabolomics Research, Kobe University Graduate School of Medicine, 7-5-1 Chu-o-ku, Kusunoki-cho, Kobe, Hyogo 650-0017, Japan. Electronic address: myoshida@med.kobe-u.ac.jp.
Abstract
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the commonest form of chronic liver disease in developed countries. Non-alcoholic steatohepatitis (NASH), which represents advanced stage NAFLD, is increasingly being recognized as a major cause of liver-related morbidity and mortality. However, no effective drugs against NASH have yet been developed. Therefore, we searched for candidate therapeutic agents based on the changes in levels of hepatic metabolites via gas chromatography mass spectrometry (GC/MS)-based metabolome analysis of livers from methionine-choline deficient (MCD) diet-fed mice, a mouse model of NASH. METHODS: The metabolites were extracted from the livers of the MCD diet-fed mice and then analyzed using GC/MS. Subsequently, the MCD diet-fed mice were supplemented with hypotaurine, and the therapeutic effects of hypotaurine against steatohepatitis were evaluated. RESULTS: Ninety-nine metabolites were detected in the livers of the MCD diet-induced steatohepatitis model mice. Among these metabolites, hypotaurine exhibited the greatest decrease in its concentration in the mice. Supplementation with 2 mmol/kgBW hypotaurine attenuated liver injuries and fat accumulation caused by the MCD diet-induced steatohepatitis. Furthermore, 10 mmol/kgBW hypotaurine supplementation ameliorated fibrosis and oxidative stress induced by the MCD diet. CONCLUSION: The present metabolome analysis-based study demonstrated that hypotaurine is a novel candidate therapeutic agent for NASH.
BACKGROUND:Non-alcoholic fatty liver disease (NAFLD) is the commonest form of chronic liver disease in developed countries. Non-alcoholic steatohepatitis (NASH), which represents advanced stage NAFLD, is increasingly being recognized as a major cause of liver-related morbidity and mortality. However, no effective drugs against NASH have yet been developed. Therefore, we searched for candidate therapeutic agents based on the changes in levels of hepatic metabolites via gas chromatography mass spectrometry (GC/MS)-based metabolome analysis of livers from methionine-choline deficient (MCD) diet-fed mice, a mouse model of NASH. METHODS: The metabolites were extracted from the livers of the MCD diet-fed mice and then analyzed using GC/MS. Subsequently, the MCD diet-fed mice were supplemented with hypotaurine, and the therapeutic effects of hypotaurine against steatohepatitis were evaluated. RESULTS: Ninety-nine metabolites were detected in the livers of the MCD diet-induced steatohepatitis model mice. Among these metabolites, hypotaurine exhibited the greatest decrease in its concentration in the mice. Supplementation with 2 mmol/kgBW hypotaurine attenuated liver injuries and fat accumulation caused by the MCD diet-induced steatohepatitis. Furthermore, 10 mmol/kgBW hypotaurine supplementation ameliorated fibrosis and oxidative stress induced by the MCD diet. CONCLUSION: The present metabolome analysis-based study demonstrated that hypotaurine is a novel candidate therapeutic agent for NASH.
Authors: Mohammad R Nezami Ranjbar; Yue Luo; Cristina Di Poto; Rency S Varghese; Alessia Ferrarini; Chi Zhang; Naglaa I Sarhan; Hanan Soliman; Mahlet G Tadesse; Dina H Ziada; Rabindra Roy; Habtom W Ressom Journal: PLoS One Date: 2015-06-01 Impact factor: 3.240
Authors: David M Wilson; Valentina Di Gialleonardo; Zhen J Wang; Valerie Carroll; Cornelius Von Morze; Andrew Taylor; Victor Sai; Mark VanCriekinge; Robert Bok; Michael A Ohliger; Kayvan R Keshari Journal: Sci Rep Date: 2017-04-20 Impact factor: 4.379